GlassScriptPhysician profile
Yasmin Bhasin
NPI 1144268749
$14,728.08
in general payments reported to CMS, 2019-2025
25 companies · $3,086 in 2025
The $3,086 reported for 2025 was more than what 77% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,168 · 2020: $365 · 2021: $1,991 · 2022: $2,513 · 2023: $2,550 · 2024: $3,057 · 2025: $3,086.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,504 · Education: $188.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,504.17 |
| Education | $188.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $5,434.17 | 2019-2025 | Tezspire, Fasenra, Airsupra |
| Genzyme Corporation | $2,279.42 | 2019-2025 | |
| Glaxosmithkline, LLC. | $2,176.07 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Regeneron Healthcare Solutions, INC. | $969.53 | 2019-2025 | Dupixent |
| Amgen INC. | $806.81 | 2021-2025 | Tezspire, Actimmune |
| Novartis Pharmaceuticals Corporation | $541.00 | 2019-2025 | |
| Optinose US, INC. | $336.48 | 2019-2022 | |
| Kaleo, INC. | $302.13 | 2019-2024 | Auvi-Q |
| Genentech USA, INC. | $284.58 | 2019-2023 | Xolair |
| Takeda Pharmaceuticals U.S.A., INC. | $246.38 | 2022-2025 | Cuvitru |
| Biohaven Pharmaceuticals, INC. | $219.84 | 2021 | |
| Ars Pharmaceuticals Operations, INC. | $200.58 | 2025 | Neffy |
| Sanofi-Aventis U.S. LLC | $150.99 | 2022-2023 | |
| Biocryst US Sales Co., LLC | $144.14 | 2022-2024 | Orladeyo |
| Csl Behring | $98.64 | 2025 | Hizentra, Andembry |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $95.29 | 2022 | |
| Blueprint Medicines Corporation | $91.66 | 2023-2024 | Ayvakit |
| Pfizer INC. | $85.15 | 2019-2022 | |
| Boston Scientific Corporation | $78.05 | 2023 | Watchman Flx |
| Aimmune Therapeutics, INC. | $59.85 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $36.70 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $28.49 | 2021 | |
| Galderma Laboratories, L.P. | $23.43 | 2025 | Nemluvio |
| Octapharma USA, INC. | $19.46 | 2025 | Cutaquig |
| Merck Sharp & Dohme LLC | $19.24 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yasmin Bhasin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.